Abstracts tagged "Laboratory tests and systemic lupus erythematosus (SLE)"

Abstract Number: 707 • 2017 ACR/ARHP Annual Meeting
Distinctive Features of Positive Anti-Cell Antibody Tests on HEp-2 Cells (HEp-2-ANA) in Patients with Non-Autoimmune Diseases
Renan Agustinelli¹, Sílvia H. Rodrigues², Mônica Prado³, Henrique Mariz⁴ and Luis Eduardo C. Andrade^5,6, ¹Rheumatology Division, Escola Paulista de Medicina, Universidade Federal de Sao Paulo, São Paulo, Brazil, ²Rheumatology Division, Escola Paulista de Medicina, Universidade Federal de São Paulo, Sao Paulo, Brazil, ³Rheumatology Division, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil, ⁴Internal Medicine Department, Hospital das Clínicas - Universidade Federal de Pernambuco, Recife, Brazil, ⁵Rheumatology Division, Universidade Federal de São Paulo, São Paulo, Brazil, ⁶Immunology Division, Fleury Medicine and Health, São Paulo, Brazil
Background/Purpose: The indirect immunofluorescence (IIF) test for anti-cell or antinuclear (ANA) antibodies on HEp-2 cells (HEp-2-ANA) is considered the gold standard method for ANA detection.…
Abstract Number: 603 • 2012 ACR/ARHP Annual Meeting
Cell Bound Complement Activation Products Are Associated with Disease Activity in Systemic Lupus Erythematosus
Kenneth C. Kalunian¹, W. Winn Chatham², Elena M. Massarotti³, Joyce Reyes-Thomas⁴, Richard Furie⁵, Jill P. Buyon⁶, Emily C. Somers⁷, Chaim Putterman⁸, Rachel L. Gross⁹, Kyriakos A. Kirou¹⁰, Rosalind Ramsey-Goldman¹¹, Christine Hsieh¹², Thierry Dervieux¹³ and A. Weinstein¹⁴, ¹UCSD School of Medicine, La Jolla, CA, ²University of Alabama at Birmingham, Birmingham, AL, ³Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Rheum/Forchheimer Rm 701, Albert Einstein College of Med, Bronx, NY, ⁵North Shore-LIJ Health System, Lake Success, NY, ⁶Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁷IntMed, Environmental Health, and OB/GYN, University of Michigan, Ann Arbor, MI, ⁸Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁹Rheumatology, Albert Einstein College of Medicine, New York, NY, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ¹²Rheumatology, University of Chicago, Chicago, IL, ¹³Research and Development, Exagen Diagnostics, Albuquerque, NM, ¹⁴Washington Hospital Center, Washington, DC
Background/Purpose: Elevated cell-bound complement activation products (CBCAPs) and decreased erythrocyte complement receptor 1 (ECR1) expression may correlate with disease activity in systemic lupus erythematosus (SLE).…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].